TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07717411: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Dis

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 1600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT07717411 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07717411 Rescue Dossier →